IMIlaria Minato

Ilaria Minato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ilaria Minato has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evidence for a Modulatory Effect of a 12‐Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof‐of‐Principle Study

    by Ilaria Minato, Pedro Mena, Luigi Ricciardiello, Eleonora Scaioli, Andrea Belluzzi, Enrica Rotondo, Eleonora Derlindati, Barbara Montanini, Costanza Michelini, Nicole Tosi, et al.

    This study aimed at investigating the effects of pomegranate juice (POMJ) consumption on inflammatory biomarkers and gene expression in patients with inflammatory bowel disease (IBD) in clinical remission. In this randomized, placebo‐controlled trial, 16 subjects with IBD in remission consumed POMJ or placebo for 12 weeks. POMJ consumption significantly reduced fecal calprotectin (FC) and plasma endotoxin levels. Transcriptomic analysis of peripheral blood mononuclear cells revealed upregulation of genes involved in mucosal immunity, including aryl hydrocarbon receptor ( AHR ), neutrophil cytosolic factor 4 ( NCF4 ), and nuclear factor, interleukin 3 regulated ( NFIL3 ). Urolithin metabotypes were predominantly of the B type, associated with intestinal dysbiosis. No significant changes were observed in serum inflammatory markers or colonic mucosal cytokine expression. POMJ consumption reduced markers of intestinal inflammation and modulated gene expression related to mucosal immunity and barrier function in patients with IBD. These findings suggest the potential of POMJ as a beneficial dietary intervention for maintaining remission in IBD, highlighting the promise of targeted nutritional strategies in managing chronic inflammatory conditions. Further research is needed to elucidate the long‐term clinical implications of these molecular changes. Trial Registration: ClinicalTrials.gov identifier: NCT03000101 .


  • Open Access

    Cerium Oxide Nanoparticles Rescue α-Synuclein-Induced Toxicity in a Yeast Model of Parkinson’s Disease

    by Roberta Ruotolo, Giuseppe De Giorgio, Ilaria Minato, Massimiliano G. Bianchi, Ovidio Bussolati, Nelson Marmiroli

    Over the last decades, cerium oxide nanoparticles (CeO2 NPs) have gained great interest due to their potential applications, mainly in the fields of agriculture and biomedicine. Promising effects of CeO2 NPs are recently shown in some neurodegenerative diseases, but the mechanism of action of these NPs in Parkinson’s disease (PD) remains to be investigated. This issue is addressed in the present study by using a yeast model based on the heterologous expression of the human α-synuclein (α-syn), the major component of Lewy bodies, which represent a neuropathological hallmark of PD. We observed that CeO2 NPs strongly reduce α-syn-induced toxicity in a dose-dependent manner. This effect is associated with the inhibition of cytoplasmic α-syn foci accumulation, resulting in plasma membrane localization of α-syn after NP treatment. Moreover, CeO2 NPs counteract the α-syn-induced mitochondrial dysfunction and decrease reactive oxygen species (ROS) production in yeast cells. In vitro binding assay using cell lysates showed that α-syn is adsorbed on the surface of CeO2 NPs, suggesting that these NPs may act as a strong inhibitor of α-syn toxicity not only acting as a radical scavenger, but through a direct interaction with α-syn in vivo.


  • Flavonoid‐Derived Human Phenyl‐γ‐Valerolactone Metabolites Selectively Detoxify Amyloid‐β Oligomers and Prevent Memory Impairment in a Mouse Model of Alzheimer's Disease

    by Roberta Ruotolo, Ilaria Minato, Pietro La Vitola, Luisa Artioli, Claudio Curti, Valentina Franceschi, Nicoletta Brindani, Davide Amidani, Laura Colombo, Mario Salmona, et al.

    Scope: Amyloid‐β oligomers (AβO) are causally related to Alzheimer's disease (AD). Dietary natural compounds, especially flavonoids and flavan‐3‐ols, hold great promise as potential AD‐preventive agents but their host and gut microbiota metabolism complicates identification of the most relevant bioactive species. This study aims to investigate the ability of a comprehensive set of phenyl‐γ‐valerolactones (PVL), the main circulating metabolites of flavan‐3‐ols and related dietary compounds in humans, to prevent AβO‐mediated toxicity.Methods and results: The anti‐AβO activity of PVLs is examined in different cell model systems using a highly toxic β‐oligomer‐forming polypeptide (β23) as target toxicant. Multiple PVLs, and particularly the monohydroxylated 5‐(4′‐hydroxyphenyl)‐γ‐valerolactone metabolite [(4′‐OH)‐PVL], relieve β‐oligomer‐induced cytotoxicity in yeast and mammalian cells. As revealed by atomic force microscopy (AFM) and other in vitro assays, (4′‐OH)‐PVL interferes with AβO (but not fibril) assembly and actively remodels preformed AβOs into nontoxic amorphous aggregates. In keeping with the latter mode of action, treatment of AβOs with (4′‐OH)‐PVL prior to brain injection strongly reduces memory deterioration as well as neuroinflammation in a mouse model of AβO‐induced memory impairment.Conclusion: PVLs, which have been validated as biomarkers of the dietary intake of flavan‐3‐ols, lend themselves as novel AβO‐selective, candidate AD‐preventing compounds.